These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 19193658)

  • 1. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis.
    Gillham MI; Sundaram S; Laughton CR; Haworth CS; Bilton D; Foweraker JE
    J Antimicrob Chemother; 2009 Apr; 63(4):728-32. PubMed ID: 19193658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.
    Foweraker JE; Laughton CR; Brown DF; Bilton D
    J Antimicrob Chemother; 2005 Jun; 55(6):921-7. PubMed ID: 15883175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media.
    Perry JD; Laine L; Hughes S; Nicholson A; Galloway A; Gould FK
    J Antimicrob Chemother; 2008 May; 61(5):1057-61. PubMed ID: 18316821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis].
    Coban AY; Ciftci A; Onuk EE; Erturan Z; Tanriverdi Cayci Y; Durupinar B
    Mikrobiyol Bul; 2009 Oct; 43(4):563-73. PubMed ID: 20084909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C; Hall M; Conway S; Peckham D; Denton M
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
    Bradbury R; Champion A; Reid DW
    Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
    Nazik H; Ongen B; Erturan Z; Salcioğlu M
    Jpn J Infect Dis; 2007 May; 60(2-3):82-6. PubMed ID: 17515637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
    Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N
    Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa from cystic fibrosis patients: study using whole cell RAPD and antibiotic susceptibility.
    Mereghetti L; Marquet-van der Mee N; Loulergue J; Rolland JC; Audurier A
    Pathol Biol (Paris); 1998 May; 46(5):319-24. PubMed ID: 9769892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High genotypic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis in the Czech Republic.
    Vosahlikova S; Drevinek P; Cinek O; Pohunek P; Maixnerova M; Urbaskova P; van den Reijden TJ; Dijkshoorn L; Nemec A
    Res Microbiol; 2007 May; 158(4):324-9. PubMed ID: 17448645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Møller NE; Høiby N
    Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel chromogenic medium for isolation of Pseudomonas aeruginosa from the sputa of cystic fibrosis patients.
    Laine L; Perry JD; Lee J; Oliver M; James AL; De La Foata C; Halimi D; Orenga S; Galloway A; Gould FK
    J Cyst Fibros; 2009 Mar; 8(2):143-9. PubMed ID: 19097827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
    Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
    Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
    King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.